Drug Trial Radar · NCT07048262
Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Sep 3, 2025
Primary completion
May 6, 2029
Study completion Jun 6, 2029
Sponsor
- Lead sponsor
- CSL BehringIndustry
- Sponsor type
- Industry
- First posted
- Jul 2, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a proof-of-concept phase 2b, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose selection study designed to explore the efficacy, safety, and tolerability of 2 active treatment regimens of CSL787 (human normal immunoglobulin G \[IgG\] inhalation solution) compared with placebo over 52 weeks. The primary aim of the study is to characterize the overall effect of CSL787 as well as the dose response of 2 active treatment regimens of inhaled CSL787 administered to participants with NCFB toward prolonging the time to first (TTF) exacerbation.
Conditions
- Non-cystic Fibrosis Bronchiectasis
Interventions
CSL787Biological
CSL787 high or low doses once daily (QD) will be administered via inhalation over a period of 52 weeks.
PlaceboDrug
Participants will receive a matching volume of placebo QD over a period of 52 weeks.
NebulizerDevice
The nebulizer is a CE-marked device.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to first (TTF) ExacerbationTime frame: Up to Week 52
Locations
13 sites in 2 countries. Site status is shown where the registry gives one.
The Prince Charles Hospital
Queensland, Australia · Recruiting
Westmead Hospital
Westmead, Australia · Recruiting
Fukuoka University Chikushi Hopsital
Chikushino-shi, Japan · Recruiting
Kyusho Central Hospital of the Mutual Aid Association of Public School Teachers
Fukuoka, Japan · Recruiting
Ibaraki Prefectural Central Hospital
Ibaraki, Japan · Recruiting
Kazunori Tobino Iizuka Hospital
Iizuka-shi, Japan · Recruiting
National Hospital Organization Minami Kyoto Hospital
Kyoto, Japan · Recruiting
Matsusaka Municipal Hospital
Mie, Japan · Recruiting
National Hospital Organization Kinki Chuo Chest Medical Center
Osaka, Japan · Recruiting
Shimonoseki City Hospital
Shimonoseki-shi, Japan · Recruiting
Japan Anti-Tuberculosis Association, Fukujuji Hospital
Tokyo, Japan · Recruiting
Keio University Hospital
Tokyo, Japan · Recruiting
National Hospital Organization Mie Chuo Medical Center
Tsu, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.